Efficacy of "Kardiovitin" in integrated treatment in arterial hypertension patients

Federal State Budgetary Scientific Institution «East-Siberian Institute of Medical and Ecological Research» 12A mikrorayon, build 3, Angarsk, Russia

^* Corresponding author: katamanova_e_v@mail.ru

Abstract

Arterial hypertension is one of the most spread chronic non-specific human diseases and according to World Health Organization, is due to 30% of all-death outcomes in general. The aim of this study was to investigate the efficacy of Kardiovitin in the integrated treatment of arterial hypertension. Methods. A total of twenty patients took part in the study - seventeen women (average age – 64.5±8.7 years, average weight – 77.8±11.4 kg) and three men (average age – 54.6±12.4 years, average weight – 114±402 kg). A questionnaire, anamnesis, study of risk factors for hypertension, ECG, general blood analysis, general urine analysis, biochemical blood tests, were included in the examination program before and after treatment. Statistical processing was carried out with the program “Statistica 6.0”. Differences at p<0.05 were considered statistically significant. Results. It was observed a statistically significant decrease in systolic blood pressure - 120.0 (120.0-130.0) at p<0.05, in total cholesterol – 5.6 (4.6-6.4), LDL cholesterol – 3.2 (3.1-3.5) at p<0.05 after 2 months Kardiovitin therapy in addition to the standard hypotensive therapy. Conclusion. The results of the study indicate the efficacy of including Kardiovitin in the scheme for basic antihypertensive therapy as a source of bioflavonoids involved in the stabilization of the vascular wall.